Pharmaco - Press Releases

Date	Title	Company
07-Dec-2021	Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th Annual 3D Cell Culture Conference	SMi Group
07-Dec-2021	Vetter Wins Frost & Sullivan’s 2021 Global Customer Value Leadership Award, and Looks Back on a Stable Year Under Ongoing Pandemic Circumstances	B3C newswire
07-Dec-2021	COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.	Cosmo Pharmaceuticals N.V.
07-Dec-2021	COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.	Cassiopea S.p.A.
06-Dec-2021	Six Key Presentations at SMi's Inaugural Robotics & Automation in Pharma Conference	SMi Group
06-Dec-2021	Original-Research: Defence Therapeutics Inc. (von GBC AG)	Defence Therapeutics Inc.
06-Dec-2021	XPhyto Therapeutics Corp.: XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH	XPhyto Therapeutics Corp.
03-Dec-2021	Tower launches “game-changing” solution for the transport of ultra cold temperature-critical pharmaceuticals	Tower Cold Chain
03-Dec-2021	Straumann Group Capital Markets Day 2021	Straumann Holding AG
03-Dec-2021	Medios AG successfully completes capital increase with gross proceeds of approximately €72 m and placement of an upsize option	Medios AG
03-Dec-2021	COSMO PHARMACEUTICALS N.V. and Cassiopea S.p.a. PUBLISH PROVISIONAL final RESULTS OF PUBLIC EXCHANGE OFFER FOR all publicly held shares of CASSIOPEA S.P.A.	Cassiopea S.p.A.
03-Dec-2021	COSMO PHARMACEUTICALS N.V. and Cassiopea S.p.a. PUBLISH PROVISIONAL final RESULTS OF PUBLIC EXCHANGE OFFER FOR all publicly held shares of CASSIOPEA S.P.A.	Cosmo Pharmaceuticals N.V.
03-Dec-2021	M1 Kliniken AG continues successful development in Q4 2021	M1 Kliniken AG
02-Dec-2021	Medios AG resolves on capital increase against cash contributions of up to 10% of the share capital	Medios AG
02-Dec-2021	SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline	B3C newswire
02-Dec-2021	Original-Research: M1 Kliniken AG (von First Berlin Equity Research GmbH)	M1 Kliniken AG
02-Dec-2021	Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock	Adrenomed AG
02-Dec-2021	ITM and Navigo Proteins Announce Research Collaboration to Develop FAP-targeting Radionuclide Therapy to Address Solid Tumors	B3C newswire
02-Dec-2021	MPH Health Care AG: result Q3-2021	MPH Health Care AG
01-Dec-2021	Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis	ABIVAX